Companies featured in this edition of the newsletter: CHIP, ENZ, GERS, IWEB, OMCM, ONEZ, XSNX

Markets hit fresh highs for ‘09 yet again last week, as the first round of earnings helped to assuage investor concerns that operating results would underpin robust gains in equities this year. All told, the Dow gained 130 points to end the week at 9995 after briefly cracking the 10,000 mark, gaining 1.3% on the week and extending its gains to 13.9% on the year. The Nasdaq gained 0.8% on the week to close at 2156, up 36.8% on the year, while the S&P 500 and Russell 2000 gained 1.5% and 0.2% respectively, bringing their YTD totals to 20.4% and 23.4%.

Earnings stole the spotlight last week as things got off to a strong start early with JP Morgan handily beating expectations calling for $0.51 per share, reporting earnings of $0.82 per share. Citigroup

DrStockPick.com Stock Report!

Tuesday August 25, 2009

**************************************************************

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that their EDC tool, TrialMaster(TM), has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the U.K., to provide eClinical services to its customers. Pleiad’s investment will provide it with the products and services to manage two upcoming studies investigating the use of ophthalmic medical devices. This partnership is expected to generate more than $1 million to OmniComm over the next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008 under

For the third straight quarter in a row, OmniComm Systems, a leader in integrated electronic data capture solutions for clinical trials, is reporting another landmark quarter for new business. The company has surpassed its previous best quarter and signed contracts through the first two quarters of 2008 totaling almost $12 million, which surpass all of the revenues brought in from last year’s signed contracts.

During the second quarter, OmniComm signed a long-term guaranteed contract with a major biotechnology company which helped to boost the company’s financials. They have also continued to increase their customer base by adding seven new clients to their customer list, and continue to see recurring business from their existing loyal customers, who have added five more trials. Finally, they have added six new partners to their very successful Preferred Partnership Programs.

“I couldn’t be happier with the current momentum and speed in which we continue to